Insider Buying: Septerna, Inc. (NASDAQ:SEPN) CFO Buys 10,500 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie bought 10,500 shares of the company’s stock in a transaction that occurred on Wednesday, February 19th. The shares were acquired at an average price of $5.51 per share, for a total transaction of $57,855.00. Following the completion of the purchase, the chief financial officer now owns 10,500 shares in the company, valued at $57,855. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Septerna Stock Performance

Septerna stock traded down $0.09 during trading hours on Friday, hitting $5.80. 1,158,707 shares of the stock traded hands, compared to its average volume of 586,476. The firm’s 50 day moving average price is $17.78. Septerna, Inc. has a 1 year low of $4.17 and a 1 year high of $28.99.

Institutional Trading of Septerna

Large investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new stake in Septerna during the 4th quarter valued at about $25,000. New York State Common Retirement Fund purchased a new stake in shares of Septerna in the fourth quarter worth about $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna in the fourth quarter worth about $42,000. Summit Investment Advisors Inc. purchased a new stake in shares of Septerna in the fourth quarter worth about $45,000. Finally, BNP Paribas Financial Markets purchased a new stake in shares of Septerna in the fourth quarter worth about $52,000.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on SEPN shares. JPMorgan Chase & Co. started coverage on Septerna in a research note on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price on the stock. TD Cowen started coverage on Septerna in a research note on Tuesday, November 19th. They set a “buy” rating on the stock. Wells Fargo & Company downgraded Septerna from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $43.00 to $14.00 in a research note on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.